A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera

A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera

Abstract Ropeginterferon alfa-2b represents a new-generation pegylated interferon-based therapy and is administered every 2–4 weeks. It is approved for polycythemia vera (PV) treatment in the United States and Europe with a starting dose of 100 µg (50 µg for patients receiving hydoxyurea) and intra-...

Full description

Bibliographic Details
Main Authors: Jie Jin, Lei Zhang, Albert Qin, Daoxiang Wu, Zonghong Shao, Jie Bai, Suning Chen, Minghui Duan, Hu Zhou, Na Xu, Sujiang Zhang, Xuelan Zuo, Xin Du, Li Wang, Pei Li, Xuhan Zhang, Yaning Li, Jingjing Zhang, Wei Wang, Weihong Shen, Oleh Zagrijtschuk, Raymond Urbanski, Toshiaki Sato, Zhijian Xiao
Format: Article
Language:English
Published: BMC 2023-06-01
Series:Experimental Hematology & Oncology
Subjects:
Ropeginterferon alfa-2b
New dosing regimen, Chinese patients with polycythemia vera
Complete hematologic response
Molecular response, JAK2 V617F allele burden
Online Access:https://doi.org/10.1186/s40164-023-00415-0

Internet

https://doi.org/10.1186/s40164-023-00415-0

Similar Items